Clinical Trial Update: Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating immunogenicity and safety of Infanrix-IPV/Hib (DTPa-IPV/Hib) in healthy Indian infants has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acellular Pertussis
• Diphtheria
• Haemophilus Influenzae Type Disease
• Poliomyelitis
• Tetanus

Drugs mentioned

• Infanrix IPV/Hib (Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae type b vaccine (DTaP-IPV-Hib))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diphtheria, Acellular Pertussis | Phase 3 | Status: WITHDRAWN